Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Gruenwald, Viktor ^a   Beutel, Gernot ^a   Schuch Jantsch, Susanne ^a   Reuter, Christoph ^a   Ivanyi, Philipp ^a   Ganser, Arnold ^a   Haubitz, Marion ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METASTASIS POTENTIAL; MONOCYTE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; BLOOD; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GERMANY; KAPLAN MEIER METHOD; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TUMOR EMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MONOCYTES; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; PYRROLES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78650666731     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-695     Document Type: Article

References (29)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124. 10.1056/NEJMoa065044, 17215529.
2. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23(5):1028-1043. 10.1200/JCO.2005.01.186, 15534359.
3. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371. 10.1038/nrm1911, 16633338.
4. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello CL, Baum CM, Deprimo SE, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007, 13:2643-2650. 10.1158/1078-0432.CCR-06-0919, 17473195.
5. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. Journal of translational medicine 2007, 5:32. 10.1186/1479-5876-5-32, 1939830, 17605814.
6. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007, 104:17069-17074. 10.1073/pnas.0708148104, 2040401, 17942672.
7. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(1):16-24. 10.1200/JCO.2005.02.2574, 16330672.
8. Woywodt A, Schroeder M, Gwinner W, Mengel M, Jaeger M, Schwarz A, Haller H, Haubitz M. Elevated numbers of circulating endothelial cells in renal transplant recipients. Transplantation 2003, 76(1):1-4. 10.1097/01.TP.0000074569.65127.26, 12865778.
9. Woywodt A, Schroeder M, Mengel M, Schwarz A, Gwinner W, Haller H, Haubitz M. Circulating endothelial cells are a novel marker of cyclosporine-induced endothelial damage. Hypertension 2003, 41(3 Pt 2):720-723. 10.1161/01.HYP.0000052948.64125.AB, 12623986.
10. Woywodt A, Scheer J, Hambach L, Buchholz S, Ganser A, Haller H, Hertenstein B, Haubitz M. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004, 103(9):3603-3605. 10.1182/blood-2003-10-3479, 14715625.
11. Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999, 93(9):2951-2958.
12. Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HM, Voest EE. Circulating endothelial cells in cancer patients do not express tissue factor. Cancer Lett 2004, 213:241-248. 10.1016/j.canlet.2004.04.019, 15327840.
13. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, Deprimo SE, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816. 10.1200/JCO.2007.14.5375, 18347007.
14. Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, Haubitz M, Dignat-George F. Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost 2006, 4(3):671-677. 10.1111/j.1538-7836.2006.01794.x, 16460450.
15. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002, 8(8):831-840.
16. Sawano A, Iwai S, Sakurai Y, Ito M, Shitara K, Nakahata T, Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001, 97(3):785-791. 10.1182/blood.V97.3.785, 11157498.
17. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott PW, Liau KF, Freddo J, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007, 8:975-984. 10.1016/S1470-2045(07)70285-1, 17959415.
18. Bhatt RS, Norden-Zfoni A, O'Neill A, Zurita AJ, Wu H, Prox D, Atkins MB, Heymach JV. Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome. J Clin Oncol 2008, 26(Suppl):Abstr 5098.
19. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97(11):3658-3661. 10.1182/blood.V97.11.3658, 11369666.
20. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, Martinelli G, Bertolini F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001, 61:4341-4344.
21. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000, 97:14608-14613. 10.1073/pnas.97.26.14608, 18966, 11121063.
22. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker S, Johnson BE, Folkman J, Heymach JV. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005, 11:3514-3522. 10.1158/1078-0432.CCR-04-2271, 15867254.
23. Vroling L, van der Veldt AA, de Haas RR, Haanen JB, Schuurhuis GJ, Kuik DJ, van Cruijsen H, Verheul HM, van den Eertwegh AJ, Hoekman K, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009, 12(1):69-79. 10.1007/s10456-009-9133-9, 19212818.
24. Hutson TE, Davis ID, Machiels JH, de Souza PL, Baker K, Bordogna W, Westlund R, Crofts T, Pandite L, Figlin RA. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26(Suppl):Abstr 5046.
25. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJ, Boven E, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008, 14(18):5884-5892. 10.1158/1078-0432.CCR-08-0656, 18794101.
26. George DJ, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Margolin K, Hutson TE, Rini BI. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007, 25(18s):Abstr 5035.
27. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000, 101:841-843.
28. Bello CL, Deprimo SE, Friece C, Smeraglia J, Sherman L, Tye L, Baum CM, Meropol NJ, Lenz H, Kulke MH. Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3. J Clin Oncol ASCO Annual Meeting Proceedings Part I 2006, 24(18s):abstr 4045.
29. Redman BG, Hudes GR, Kim ST, Chen I, Motzer RJ. Sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): Updated results from a phase I/II study. J Clin Oncol 2008, 26(Suppl):Abstr 16014.